Together, these findings suggest that, despite potential context-dependent risks, DNMT inhibitors such as decitabine and azacitidine can favorably modulate the bone microenvironment and tumor–stroma interactions, offering a promising epigenetic approach to impede skeletal colonization and progression. This evidence concerns the gene DNMT1 and neoplasm.